FDA Panel Supports Tazemetostat for Epithelioid Sarcoma

The FDA’s Oncologic Drugs Advisory Committee voted in favor of approving tazemetostat tablets as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.

Read the full article here

Related Articles